0001140361-17-016029.txt : 20170417
0001140361-17-016029.hdr.sgml : 20170417
20170417182521
ACCESSION NUMBER: 0001140361-17-016029
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170414
FILED AS OF DATE: 20170417
DATE AS OF CHANGE: 20170417
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kavanaugh William Michael
CENTRAL INDEX KEY: 0001578767
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 17765571
MAIL ADDRESS:
STREET 1: C/O FIVE PRIME THERAPEUTICS, INC.
STREET 2: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2017-04-14
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001578767
Kavanaugh William Michael
151 OYSTER POINT BLVD.
SUITE 400
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
CSO, Head Res.&Non-Clin. Dev.
Stock Option (Right to Buy)
4.4728
2017-04-14
4
A
0
48368
0.00
A
2025-05-06
Common Stock
48368
96736
D
On May 7, 2015, the Reporting Person was granted an option to purchase 96,736 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On September 26, 2016, the first performance milestone was achieved resulting in 50% of the Performance Option vesting. On April 14, 2017, the second performance milestone was achieved resulting in the remaining 50% of the Performance Option vesting.
/s/ Cynthia J. Ladd, as Attorney-in-Fact for Michael Kavanaugh
2017-04-17